ADVANCED LIFE SCIENCES TO STUDY CETHROMYCIN FOR ANTHRAX

摘要

Advanced Life Sciences Holdings,Inc.(Nasdaq:ADLS),Chicago,has announced the commencement of its collaboration with the National Institute of Allergy and Infectious Diseases(NIAID),the lead governmental institute supporting biodefense research,under which the NIAID will conduct studies to evaluate cethromycin,the company's late-stage antibiotic,as a treatment for anthrax and other high-priority biodefense agents.This collaboration is part of the U.S.Government's effort to accelerate the research and development of medical countermeasures through the crucial phase of drug development under Project BioShield.All studies conducted under this partnership will be funded by the NIAID and will be performed by its contract testing laboratories.